VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment Posted byZacks Equity Research February 25, 2022 Leave a comment on VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.